Search
Formebolone
go.drugbank.com/drugs/DB01569IllicitInvestigationalIt has been used experimentally in the treatment of growth retardation, and has been noted to increase bone mass. … It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes.
Farnesol
go.drugbank.com/drugs/DB02509Investigational(From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) … A colorless liquid extracted from oils of plants such as citronella, neroli, cyclamen, and tuberose.
KB3305
go.drugbank.com/drugs/DB06349ExperimentalKB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.
Synonyms: (4R)-4-((3S,5R,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-DIHYDROXY-3-(2-(4-((8S,11R,13S,14S,17S)-17-HYDROXY-13-METHYL-3-OXO-17-PROP-1-YNYL-1,2,6,7,8,11,12,14,15,16-DECAHYDROCYCLOPENTA(A)PHENANTHREN-11-YL)-N-METHYL-ANILINOPerospirone
go.drugbank.com/drugs/DB08922InvestigationalIt is also shown to be less associated with extrapyramidal symptoms as a side effect compared to [DB00502]. … It is commonly present as the hydrated hydrochloride salt form.
Synonyms: cis-N-(4-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cyclohexanedicarboximideFavId
go.drugbank.com/drugs/DB05249InvestigationalFavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.
MKC1106-PP
go.drugbank.com/drugs/DB06030ExperimentalMKC1106-PP was under investigation in clinical trial NCT00423254 (Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.).
2-hydroxy-6-oxo-6-phenyl-2,4-hexadienoic acid
go.drugbank.com/drugs/DB07914ExperimentalMetabolic product of biphenyl; from Pseudomonas putida.
Arbaclofen Placarbil
go.drugbank.com/drugs/DB08892InvestigationalIt was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties. … by XenoPort in 2011 for the treatment of GERD.
Fasinumab
go.drugbank.com/drugs/DB12157Investigational[A241165] NGF was first discovered in the 1950s[A241180] and was the first neurotrophic factor to be identified and biochemically characterized. … It is currently under investigation for the treatment osteoarthritic pain[A241045] and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e
Hexylcaine
go.drugbank.com/drugs/DB00473ApprovedWithdrawnPatients experience an overdose may present with headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.